November 10, 2015 7:18pm

 

The challenge is there isn’t a sense of equity fortitude as sharp pricing run ups are followed by equally sharp declines

Probabilities become reality too often! Subscription required, read more … http://www.regmedinvestors.com/user/register

 

 

I say today what others won't, so you can do what others can't - access insight into sector sentiment and share pricing! The time has come to SUBSCRIBE!  Can you afford not to?

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

 

The major averages ended mixed Tuesday after spending most of the day in the red amid concerns over whether the Federal Reserve will raise interest rates next month.

The NASDAQ fell 0.2%, but came well off its early lows, while the Dow and the S&P 500 each ended up 2% after reversing early losses. Volume was mixed in the stock market today, rising 3% on the NASDAQ and slipping 7% on the NYSE compared to Monday.

Stocks have been buffeted in recent days as investors weighed whether the economy is strong enough to withstand a possible Fed rate hike next month. Rate-hike bets got a boost Friday after employers added many more jobs than expected last month.

The NASDAQ closed DOWN -12.06 or -0.24% to 5,083.24 and the DOW or -27.73 or -0.16% to 17,758.21.

 

 

Henry’omics:

  • The stem, cell and gene therapy RegMed sector opened - negative again with the Advance/Decline Line dipping throughout the session to the downside to close in negative territory;
  • My fear gauge – The CBOE Volatility Index (VIX) barely moved on Tuesday to near 15 from Monday’s below 15 following Friday’s above 16.

 

 

Earnings:

Most would agree the fundamental situation has not changed much, with exception of a handful of “so-so” received financial results/earnings reports, which is different than the previous quarter:

  • Northwest Bio (NWBO) reported <11/9> a Q3/15 net income of $22.6 M or -$0.19 per share with $7.1 M in cash;
  • ImmunoCellular Therapeutics (NYSEMKT: IMUC) reported <11/10> a Q3/15 net loss of -$3.4 M or -$0.04 per share with $24.4 M in cash. IMUC closed down -$0.02 to $0.408.
  • Juno Therapeutics (JUNO) reported <11/10> a Q3/15 net loss of -$23.24 M or -$0.26 per share with $1.27 billion in cash. JUNO closed down -$0.07 to $51.38.
  • Organovo (ONVO) reported <11/10> a Q3/15 net loss of -$11.3 M or -$0.12 per share with $76.9 M in cash ONVO closed down -$0.05 to $3.18.
  • Opexa (OPXA) reported <11/10> a Q3/15 net loss of -$2.8 M or -$0.42 per share with $15.59 M in cash OPXA closed down -$0.01 to $3.26.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • The SCGT & RM equities opened negative with an Advance/Decline line (A/DL) of 12/27 and 4 flats;
  • The mid-day continued negative with an A/DL of 17/25 and 1 flat;
  • The closing bell rang negative to end the session with an A/DL of 14/27 and 2 flats.

 

 

Tuesday’s trading indications:  2 hits/ 4 miss

  • Asterias (NYSEMKT: AST) closed DOWN – miss;
  • bluebird bio (BLUE) closed DOWN – hit;
  • Cellectis S.A.  ADR (CLLS) closed DOWN – miss;
  • Intrexon (XON) closed UP – miss;
  • Organovo (ONVO) closed DOWN – hit;
  • Verastem (VSTM) closed DOWN – miss;

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed UP Tuesday +1.38 or +0.42% following Monday’s advance of +0.34 or +0.10%;
  • The NASDAQ Biotechnology index (NBI) closed UP Tuesday 13.99 or +0.40% following Monday’s advance of +2.30 or +0.07%;
  • The Russell 2000 (IWM) closed UP Tuesday +0.35 or +0.30% following Monday’s decline of -1.40 or -1.17%;
  • The SPDR SD&P Biotech ETF (XBI) closed DOWN Tuesday -0.25 or -0.35% following Monday’s advance of +0.63 or +0.89%;

 

 

Dosing the sector – what a day for the 43 Patients:

  • Open: NEGATIVE with 27 decliners, 12 advances and 4 flats;
  • Mid-day (1 pm): NEGATIVE with 25 decliners, 17 advancers and 1 flat;
  • Closing bell: NEGATIVE with 27 decliner, 14 advancers and 2 flats

 

 

Who was UP – top 5:

  • Kite Pharma (KITE) closed up +$5.18 to $82.67;
  • Ocata Therapeutics (ONCE) +$0.3.98 to $8.44;
  • Bellicum (BLCM) +$3.08 to $19.84;
  • Intrexon (XON) +$3.02 to $42.80;
  • Applied Genetic Technologies (AGTC) closed up +$1.53 to $15.34

 

 

Who closed down – top 5:

  • Cellectis ADR (CLLS) closed down -$2.38 to $37.63;
  • Avalanche (AAVL) -$1.37 to $7.99;
  • Bluebird bio (BLUE) -$0.86 to $75.38;
  • VistaGen (VSTA) -$0.50 to $6.25;
  • Sangamo (SGMO) closed down -$0.40 to $7.58

 

 

Flat:

  • BioTime (NYSEMKT: BTX) at $3.55;
  • Mesoblast ADR (USOTC: MBLTY) at $12.33;

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.